Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1sargramostim 1pentetreotide 1olaparib 1lutetium Lu 177 dotatate 1entinostat 1aldesleukin 1Surgical Procedures, Operative 1Semaxinib 1Ritonavir 1Radiotherapy 1Photochemotherapy 1Paclitaxel 1Indinavir 1Gefitinib 1Fentanyl 1Docetaxel 1Congresses as Topic 12-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esthesioneuroblastoma, Olfactory × Semaxinib × Endocrine × Clear all
NCT00005647 2010-06-10

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Case Comprehensive Cancer Center

Phase 1 Completed
12 enrolled
CNSEndocrineHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡